FeedworthyAI
Science

BioPharm International articles

biopharminternational.com

BioPharm International articles

newsScience

Articles100

<![CDATA[Flexibility and AI-driven Diligence Are Defining Biopharma Deal Strategy in 2026, Says Baker McKenzie's Oren Livne]]>

<![CDATA[Drug Digest: How Advanced Analytics Partnerships Enhance the Biopharma Value Chain]]>

<![CDATA[Executive Summary: The Road Ahead: What's Next for Host Cell Protein Analytics?]]>

<![CDATA[Why Gout's Straightforward Biology and Large Unmet Need Make It an Overlooked Drug Development Opportunity, says Dr James Mackay, Crystalys Therapeutics CEO]]>

<![CDATA[Novel Payloads and Multispecific Antibodies Fuel ADC Innovation]]>

<![CDATA[Beyond the Strip: Las Vegas Has a New Kind of Venture in Mind]]>

<![CDATA[Why CGT Manufacturing Still Faces Process Characterization and Scale-Up Challenges, According to MilliporeSigma’s Sebastián Arana]]>

<![CDATA[Human-Based Preclinical Models May Improve Toxicity Prediction in Oncology Development]]>

<![CDATA[Thermo Fisher Scientific’s Dr Anil Kane Discusses How AI and Strategic Partnerships Are Reshaping Contract Drug Development at BIO 2026]]>

<![CDATA[Trop-2-Directed ADC Sacituzumab Govitecan Earns FDA Approval in First-Line Metastatic Triple-Negative Breast Cancer]]>

<![CDATA[Formulating for Function: Strategies to Maximize Stability of Emerging Biologics]]>

<![CDATA[ReAlta CEO, Dr Howard Berman, Discusses How Complement, Neutrophil, and Myeloperoxidase Inhibition May Transform HIE Treatment]]>

<![CDATA[Building a Strong Data Foundation for AI in Drug Manufacturing]]>

<![CDATA[How Safety and Biomarkers Are Shaping the Next Generation of ADCs]]>

<![CDATA[Flexible Manufacturing and Workforce Modernization are Top Bioproduction Priorities, Says MilliporeSigma’s Sebastián Arana]]>

<![CDATA[Addressing False Positives in Sequence Variant Analysis]]>

<![CDATA[The BioPharm Brief: Fibrosis, Bispecific ADCs, and Billion-Dollar Deals]]>

<![CDATA[Can Organoids and Human-Based Models Improve Drug Development Predictability?]]>

<![CDATA[Translatable Single-Cell Data, Not Volume, Drive Therapeutic Antibody Platform Decisions, Says Dr Wyatt McDonnell of Infinimmune]]>

<![CDATA[Mediar Advances First-in-Class Anti-SMOC2 Antibody MTX-439 Into Phase 1 Trial for CKD-Associated Fibrosis]]>

<![CDATA[China NMPA Approves Iza-bren for Nasopharyngeal Carcinoma, Marking First Global Bispecific ADC Approval]]>

<![CDATA[AbbVie to Acquire Apogee Therapeutics for $10.9 Billion, Gaining IL-13 Antibody Zumilokibart]]>

<![CDATA[Infinimune CEO Dr Wyatt McDonnell on Leveraging the Human Immune System for Therapeutic Antibody Discovery]]>

<![CDATA[The BioPharm Brief: Triple Threats, TL1A Bets, and AI Brains]]>

<![CDATA[Improving ADC Tolerability Could Expand Long-Term Cancer Treatment Options]]>

<![CDATA[Innovent's Trispecific Antibody IBI3003 Advances Into Phase 3 for Relapsed or Refractory Multiple Myeloma]]>

<![CDATA[Bionyra Pharma Launches with $165M and Two TL1A Biologics Licensed From TrueLab, Entering Crowded IBD Race]]>

<![CDATA[Insilico Medicine and SK Biopharmaceuticals Form AI-Powered Drug Discovery Collaboration for Neuroimmune CNS Disorders]]>

<![CDATA[Precision Medicine Strategies Expand Opportunities for Targeted Cancer Treatment, Says Dr Oren Gilad, Aprea Therapeutics]]>

<![CDATA[Replacing the Mouse, Hamster and Rat Antibody Production Tests (MAP, HAP, RAP) with Next Generation Sequencing iDTECT® Transcriptome assay]]>

<![CDATA[Takeda to Deploy Boltz Biomolecular AI Models in Drug Discovery Research]]>

<![CDATA[Japan Approves Subcutaneous Formulation of Sanofi's Sarclisa for Multiple Myeloma, Marking Second Global Regulatory Win]]>

<![CDATA[FDA Advisory Panel Votes 9-0 in Favor of Moderna's mRNA Flu Vaccine, Setting Stage for August Decision]]>

<![CDATA[The BioPharm Brief: FDA Decisions, Vaccine Momentum, and Lymphoma Advances]]>

<![CDATA[Switzerland Innovation Park Targets Growth Through Collaborative Biopharma Infrastructure]]>

<![CDATA[Cencora Experts Discuss Regulatory and Supply Chain Challenges in Radiopharmaceutical Distribution]]>

<![CDATA[FDA Accepts Roche's Application for Lunsumio and Polivy Combination in Relapsed or Refractory Large B-Cell Lymphoma]]>

<![CDATA[FDA Approves Merck’s Pneumococcal 21-Valent Conjugate Vaccine for High-Risk Children and Adolescents Aged 2 Through 17]]>

<![CDATA[FDA Advisory Panel Convenes Today to Weigh Moderna's mRNA-Based Flu Vaccine]]>

<![CDATA[Commercializing at FDA Speed in Emerging Biopharma]]>

<![CDATA[What It Takes to Support Emerging Biopharma Programs Through Rapid Candidate Identification]]>

<![CDATA[CellxLife Licenses Mayo Clinic FRα-Targeting Dendritic Cell Vaccine for Ovarian Cancer]]>

<![CDATA[LG AI Research, D&D Pharmatech Partner to Advance AI-Driven Oral Peptide Drug Discovery]]>

<![CDATA[Jazz, AbCellera Partner to Develop Multispecific T-Cell Engagers for Gastrointestinal Cancers and Solid Tumors]]>

<![CDATA[Biosimilar Erosion Driving Uptake of Process Intensification]]>

<![CDATA[Q&A: Cytiva’s Pierre-Alain Ruffieux on Scaling Cell and Gene Therapy Manufacturing for Global Access]]>

<![CDATA[The BioPharm Brief: Dual Targets, Treg Therapy, Tumor Responses]]>

<![CDATA[Bambusa Reports Positive Phase 1 Data for Dual-Targeting Bispecific Antibody BBT002 in Type 2 Inflammatory Diseases]]>

<![CDATA[HCW9302, HCW Biologics’ IL-2Rα-Biased Fusion Immunotherapeutic, Shows Preliminary Clinical Activity in Phase 1 Alopecia Areata Trial with Favorable Early Safety Profile]]>

<![CDATA[Context Therapeutics Reports 29% Response Rate for CTIM-76 in Platinum-Resistant Ovarian Cancer Phase 1 Trial]]>

<![CDATA[Talquetamab Plus Daratumumab Combination Reduces Progression Risk by Up to 72% in Phase 3 Relapsed Multiple Myeloma Trial ]]>

<![CDATA[The BioPharm Brief: Hormones, Metabolism, Momentum]]>

<![CDATA[Novartis Reports Positive Phase 1/2 Biomarker Data for Delpacibart Braxlosiran in Facioscapulohumeral Muscular Dystrophy]]>

<![CDATA[One-Year Canvuparatide Data Support Once-Weekly PTH Replacement Approach in Chronic Hypoparathyroidism]]>

<![CDATA[Insulin Ludefen and GLP-1 Bofanglutide Meet Metabolic Disease Trial Endpoints]]>

<![CDATA[The BioPharm Brief: CAR-T Progress, ADC Momentum, Biosimilar Expansion]]>

<![CDATA[Radiopharmaceutical Logistics and Manufacturing Advances Fuel Growth in Targeted Cancer Therapies]]>

<![CDATA[6 Key Developments Shaping mRNA Therapeutics Beyond COVID-19 Vaccines]]>

<![CDATA[Imviva Reports High Response Rates for Off-the-Shelf CAR-T Therapy CTD402 in Relapsed or Refractory T-ALL/LBL]]>

<![CDATA[Immunome Doses First Patient in Phase 1 Trial of Potential First-in-Class ADC IM-1617 for Advanced Solid Tumors]]>

<![CDATA[FDA Expands Tocilizumab Biosimilar's Label to CRS and Pediatric COVID-19]]>

<![CDATA[BioPharm Brief: Dermatology, Neurology, and Oncology Updates]]>

<![CDATA[Kyowa Kirin Highlights New Mogamulizumab Data in Cutaneous T-Cell Lymphoma at WCCL 2026]]>

<![CDATA[FDA Approves Lebrikizumab Every-8-Week Maintenance Dosing for Moderate-to-Severe Atopic Dermatitis ]]>

<![CDATA[Sanofi Halts Phase 3 CIDP Study of Riliprubart After Futility Analysis]]>

<![CDATA[The Ron Lanton Report: From Innovation to Infrastructure]]>

<![CDATA[BioPharm Brief: RNAi, Obesity, and Diabetes Advances]]>

<![CDATA[Lilly's Oral GLP-1 Foundayo Outperforms Oral Semaglutide in Phase 3 Type 2 Diabetes Trial]]>

<![CDATA[City Therapeutics Advances RNAi Pipeline as CITY-FXI Enters Clinic and Stargardt Program Approaches IND]]>

<![CDATA[Survodutide Reduces Visceral and Liver Fat in Phase 3 Obesity and MASLD Trials]]>

<![CDATA[The BioPharm Brief: Myeloma, Hemophilia, and KRAS]]>

<![CDATA[Johnson & Johnson to Acquire Firefly Bio for $1 Billion to Expand KRAS-Focused Oncology Pipeline]]>

<![CDATA[FDA Expands Pfizer’s Hympavzi Approval to Pediatric Hemophilia Patients and Those with Inhibitors]]>

<![CDATA[EC Approves Sanofi’s Subcutaneous Isatuximab for Multiple Myeloma Across All Existing Indications ]]>

<![CDATA[FAQ: What You Need to Know About AI and Analytical Innovation in Biopharma Development ]]>

<![CDATA[The BioPharm Brief: Biosimilars, Stem Cells, and Checkpoints]]>

<![CDATA[TIGIT review highlights unresolved questions for pancreatic cancer immunotherapy]]>

<![CDATA[FDA Approves Lupin’s Interchangeable Ranibizumab Biosimilar Ranluspec for Multiple Retinal Diseases]]>

<![CDATA[Made Scientific, Pluristyx Partner on iPSC Cell Therapy Manufacturing]]>

<![CDATA[An Innovative, Modular Approach to Flexible Supply Chain Management]]>

<![CDATA[Becoming a Cornerstone of Fujifilm’s CDMO Strategy in Denmark]]>

<![CDATA[How Integrated Biologics Manufacturing Ecosystem Is Redefining Speed, Scale, and Sustainability]]>

<![CDATA[How Advanced Manufacturing Strategies Can Support Next-Generation Antibody-Drug Conjugate Innovation]]>

<![CDATA[The BioPharm Brief: Breakthroughs, Bispecifics, and Biosimilars]]>

<![CDATA[A Q&A with Dr. Ganesh Bala on LC–MS and Multi-Attribute Methods for Bioconjugate CQA Monitoring]]>

<![CDATA[Teva launches Ahzantive aflibercept biosimilar for retinal diseases in Europe]]>

<![CDATA[CytomX and Regeneron Expand Collaboration on Tumor-Activated Bispecific Cancer Therapies]]>

<![CDATA[Biogen’s Salanersen Earns FDA Breakthrough Therapy Designation for SMA]]>

<![CDATA[The BioPharm Brief: RNA Editing, Cardiac Remodeling, Rare Disease Gene Therapy]]>

<![CDATA[From Visibility to Design: What Sweden Reveals About Building ATMP Systems ]]>

<![CDATA[EHMT1 Gene Therapy for Kleefstra Syndrome Enters Preclinical Collaboration]]>

<![CDATA[Lilly Licenses Ascidian RNA Rxon-Editing Platform for Inherited Kidney Diseases]]>

<![CDATA[Tenaya Reports Interim TN-201 Data in MYBPC3-Associated HCM]]>

<![CDATA[Ensuring the highest purity in injectable formulations with MaxiPure® Polysorbate 80]]>

<![CDATA[The BioPharm Brief: Gene Therapy Reform, Cancer Trial Endpoints, and a $1.2B Rare Disease Deal]]>

<![CDATA[Eli Lilly Signs Up to $1.2B Licensing Deal for Hanmi GLP-2 Therapy in Short Bowel Syndrome]]>

<![CDATA[FDA Draft Guidance Could Streamline Rare Disease Gene Therapy Development]]>

<![CDATA[Basel Innovation Park Main Campus Expands Flexible Infrastructure for Biopharma Startups and Manufacturing]]>

<![CDATA[The New BioPharma Playbook: Seven Technologies Defining Drug Development in 2026]]>

<![CDATA[Izalontamab Brengitecan Meets Dual Survival Endpoints in Phase 3 TNBC and Esophageal Cancer Trials]]>